Gut microbiota in hepatitis B cirrhosis

Yannan LI; Changzheng LI

doi:10.12449/JCH250324

Volume 41 Issue 3

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(3): 552-555

PDF( 554 KB)

Gut microbiota in hepatitis B cirrhosis

DOI: 10.12449/JCH250324

Yannan LI¹,
Changzheng LI^{2
,
,
,}

1.
Department of Gastroenterology，Training Base for Postgraduate Students，PLA Rocket Force Characteristic Medical Center of Jinzhou Medical University，Beijing 100088，China
2.
Department of Gastroenterology，PLA Rocket Force Characteristic Medical Center，Beijing 100088，China

Research funding:

Independent Research Project of Chinese People’s Liberation Army Rocket Force Characteristic Medical Center (25FC003)

More Information

Corresponding author: LI Changzheng， licz435@163.com （ORCID： 0009-0001-3771-6155）
Received Date: 2024-06-07
Accepted Date: 2024-07-24
Published Date: 2025-03-25

Abstract

Abstract

Hepatitis B cirrhosis is the most significant component of liver cirrhosis in China， and there is a significant increase in the mortality rate of patients after progression from hepatitis to liver cirrhosis. A large number of studies have shown that gut microbiota may influence the progression of hepatitis B cirrhosis， including the impact on the regulation of inflammatory response and intestinal immunity， the inhibition of HBV， and the production of ammonia-like substances. This article reviews the research advances in the changes in gut microbiota in hepatitis B cirrhosis patients and explores new ideas for the treatment of hepatitis B cirrhosis by intervening in gut microbiota.
- Hepatitis B,
- Liver Cirrhosis,
- Gastrointestinal Microbiome,
- RNA， Ribosomal， 16S

FullText(HTML)

References(29)

References

[1]	TRANAH TH, EDWARDS LA, SCHNABL B, et al. Targeting the gut-liver-immune axis to treat cirrhosis[J]. Gut, 2021, 70( 5): 982- 994. DOI: 10.1136/gutjnl-2020-320786.
[2]	SHEN Y, WU SD, CHEN Y, et al. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response[J]. Gut Microbes, 2023, 15( 1): 2155018. DOI: 10.1080/19490976.2022.2155018.
[3]	ZENG YB, CHEN SJ, FU Y, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Viral Hepat, 2020, 27( 2): 143- 155. DOI: 10.1111/jvh.13216.
[4]	CHEN B, HUANG H, PAN CQ. The role of gut microbiota in hepatitis B disease progression and treatment[J]. J Viral Hepat, 2022, 29( 2): 94- 106. DOI: 10.1111/jvh.13595.
[5]	SUNG CM, LIN YF, CHEN KF, et al. Predicting clinical outcomes of cirrhosis patients with hepatic encephalopathy from the fecal microbiome[J]. Cell Mol Gastroenterol Hepatol, 2019, 8( 2): 301- 318. e 2. DOI: 10.1016/j.jcmgh.2019.04.008.
[6]	GUO ZW, ZHANG JX, LI S, et al. Research advances in intestinal flora and the development and prognosis of chronic hepatitis B[J]. J Clin Hepatol, 2022, 38( 5): 1137- 1142. DOI: 10.3969/j.issn.1001-5256.2022.05.034. 郭紫薇, 张嘉鑫, 李硕, 等. 肠道菌群与慢性乙型肝炎发生发展及预后的关系[J]. 临床肝胆病杂志, 2022, 38( 5): 1137- 1142. DOI: 10.3969/j.issn.1001-5256.2022.05.034.
[7]	LI YG, YU ZJ, LI A, et al. Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: Molecular mechanisms and therapeutic inventions[J]. World J Gastroenterol, 2022, 28( 28): 3555- 3572. DOI: 10.3748/wjg.v28.i28.3555.
[8]	MILOSEVIC I, RUSSO E, VUJOVIC A, et al. Microbiota and viral hepatitis: State of the art of a complex matter[J]. World J Gastroenterol, 2021, 27( 33): 5488- 5501. DOI: 10.3748/wjg.v27.i33.5488.
[9]	LIU SY, YANG XL. Intestinal flora plays a role in the progression of hepatitis-cirrhosis-liver cancer[J]. Front Cell Infect Microbiol, 2023, 13: 1140126. DOI: 10.3389/fcimb.2023.1140126.
[10]	WU LL, HUANG TS, SHYU YC, et al. Gut microbiota in the innate immunity against hepatitis B virus-implication in age-dependent HBV clearance[J]. Curr Opin Virol, 2021, 49: 194- 202. DOI: 10.1016/j.coviro.2021.06.006.
[11]	ZHU RR, LIU LW, ZHANG GZ, et al. The pathogenesis of gut microbiota in hepatic encephalopathy by the gut-liver-brain axis[J]. Biosci Rep, 2023, 43( 6): BSR20222524. DOI: 10.1042/BSR20222524.
[12]	KOH A, de VADDER F, KOVATCHEVA-DATCHARY P, et al. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites[J]. Cell, 2016, 165( 6): 1332- 1345. DOI: 10.1016/j.cell.2016.05.041.
[13]	WU S, CHEN SJ, LIN JP, et al. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis[J]. Ann Hepatol, 2022, 27( 2): 100676. DOI: 10.1016/j.aohep.2022.100676.
[14]	PANT K, MISHRA AK, PRADHAN SM, et al. Butyrate inhibits HBV replication and HBV-induced hepatoma cell proliferation via modulating SIRT-1/Ac-p53 regulatory axis[J]. Mol Carcinog, 2019, 58( 4): 524- 532. DOI: 10.1002/mc.22946.
[15]	CAI JW, RIMAL B, JIANG CT, et al. Bile acid metabolism and signaling, the microbiota, and metabolic disease[J]. Pharmacol Ther, 2022, 237: 108238. DOI: 10.1016/j.pharmthera.2022.108238.
[16]	WANG XL, CHEN L, WANG H, et al. Modulation of bile acid profile by gut microbiota in chronic hepatitis B[J]. J Cell Mol Med, 2020, 24( 4): 2573- 2581. DOI: 10.1111/jcmm.14951.
[17]	ROAGER HM, LICHT TR. Microbial tryptophan catabolites in health and disease[J]. Nat Commun, 2018, 9( 1): 3294. DOI: 10.1038/s41467-018-05470-4.
[18]	WANG YX, PAN CQ, XING HC. Advances in gut microbiota of viral hepatitis cirrhosis[J]. Biomed Res Int, 2019, 2019: 9726786. DOI: 10.1155/2019/9726786.
[19]	YOSHIO S, SUGIYAMA M, SHOJI H, et al. Indoleamine-2, 3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B[J]. Hepatology, 2016, 63( 1): 83- 94. DOI: 10.1002/hep.28282.
[20]	SUN X, PAN CQ, XING H. Effect of microbiota metabolites on the progression of chronic hepatitis B virus infection[J]. Hepatol Int, 2021, 15( 5): 1053- 1067. DOI: 10.1007/s12072-021-10230-6.
[21]	LANG PA, CONTALDO C, GEORGIEV P, et al. Aggravation of viral hepatitis by platelet-derived serotonin[J]. Nat Med, 2008, 14( 7): 756- 761. DOI: 10.1038/nm1780.
[22]	KWAK DS, JUN DW, SEO JG, et al. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease[J]. Eur J Gastroenterol Hepatol, 2014, 26( 12): 1353- 1359. DOI: 10.1097/MEG.0000000000000214.
[23]	LIU YH, CHEN KF, LI FY, et al. Probiotic Lactobacillus rhamnosus GG prevents liver fibrosis through inhibiting hepatic bile acid synthesis and enhancing bile acid excretion in mice[J]. Hepatology, 2020, 71( 6): 2050- 2066. DOI: 10.1002/hep.30975.
[24]	LEE DK, KANG JY, SHIN HS, et al. Antiviral activity of Bifidobacterium adolescentis SPM0212 against hepatitis B virus[J]. Arch Pharm Res, 2013, 36( 12): 1525- 1532. DOI: 10.1007/s12272-013-0141-3.
[25]	BAJAJ JS, KASSAM Z, FAGAN A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial[J]. Hepatology, 2017, 66( 6): 1727- 1738. DOI: 10.1002/hep.29306.
[26]	WEI Q, YANG JN, HE XL, et al. Role and potential mechanism of fecal microbiota transplantation in treatment of chronic hepatitis B[J]. Chin J Pathophysiol, 2020, 36( 10): 1833- 1843. DOI: 10.3969/j.issn.1000-4718.2020.10.015. 魏琦, 杨静楠, 何学良, 等. 粪便菌群移植在慢性乙肝治疗中的作用及机制[J]. 中国病理生理杂志, 2020, 36( 10): 1833- 1843. DOI: 10.3969/j.issn.1000-4718.2020.10.015.
[27]	ACHARYA C, BAJAJ JS. Altered microbiome in patients with cirrhosis and complications[J]. Clin Gastroenterol Hepatol, 2019, 17( 2): 307- 321. DOI: 10.1016/j.cgh.2018.08.008.
[28]	TREBICKA J, MACNAUGHTAN J, SCHNABL B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. J Hepatol, 2021, 75( Suppl 1): s67- s81. DOI: 10.1016/j.jhep.2020.11.013.
[29]	PONZIANI FR, ZOCCO MA, D’AVERSA F, et al. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation[J]. World J Gastroenterol, 2017, 23( 25): 4491- 4499. DOI: 10.3748/wjg.v23.i25.4491.

Relative Articles

[1]	Jiongjiong BI, Yingjie MA. Characteristics of the composition of intestinal flora in cirrhotic patients with malnutrition[J]. Journal of Clinical Hepatology, 2024, 40(1): 83-88. doi: 10.12449/JCH240115
[2]	Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis： Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
[3]	Jiangkai LIU, Yameng NIU, Suling LI, Qingliang MA, Jiangwen ZHANG, Yaru ZHANG, Bingqian LI. Effect of Jiedu Huayu Tongfu prescription on intestinal flora in patients with hepatitis B cirrhosis with liver-gallbladder damp-heat syndrome[J]. Journal of Clinical Hepatology, 2022, 38(4): 821-827. doi: 10.3969/j.issn.1001-5256.2022.04.016
[4]	Guochao NIU, Donglei SUN, Xiaolan ZHANG. Influence of small intestinal bacterial overgrowth on liver cirrhosis and its treatment[J]. Journal of Clinical Hepatology, 2022, 38(9): 2146-2149. doi: 10.3969/j.issn.1001-5256.2022.09.038
[5]	Hui DENG, Bin ZHANG, Bin ZHU, Zhayier DILIHUMAER, Weixian WANG, Chunxia GUO, Dongliang YANG, Xin ZHENG, Junzhong WANG, Baoju WANG. Research advances in the role of gut microbiota in chronic hepatitis B, chronic hepatitis C, and related liver diseases[J]. Journal of Clinical Hepatology, 2022, 38(5): 1143-1147. doi: 10.3969/j.issn.1001-5256.2022.05.035
[6]	Ziwei GUO, Jiaxin ZHANG, Shuo LI, Xiaobin LI, Shun ZHU, Qian JIN, Xiaoke LI, Yongan YE. Research advances in intestinal flora and the development and prognosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(5): 1137-1142. doi: 10.3969/j.issn.1001-5256.2022.05.034
[7]	Lingyan XIAO, Awen XING, Shanzhong TAN. Research advances in the association between liver failure and intestinal barrier injury[J]. Journal of Clinical Hepatology, 2021, 37(11): 2710-2714. doi: 10.3969/j.issn.1001-5256.2021.11.049
[8]	Yanyan CHEN, Yanmei LAN, Minggang WANG, Dewen. MAO. Mechanism of action of bile acid-farnesoid X receptor-intestinal microecological axis in the development of liver failure and liver regeneration[J]. Journal of Clinical Hepatology, 2021, 37(2): 480-484. doi: 10.3969/j.issn.1001-5256.2021.02.049
[9]	Menghao LI, Kai LI, Shihao TANG, Zhengyu WANG, Wengang GUO, Zhanxin YIN, Guohong HAN. Changes in gut microbiota after transjugular intrahepatic portosystemic shunt in cirrhotic patients with mild hepatic encephalopathy in different prognosis groups[J]. Journal of Clinical Hepatology, 2021, 37(2): 326-330. doi: 10.3969/j.issn.1001-5256.2021.02.016
[10]	Ceng ShengLan, Lu: Chao, Xiao WeiSong, Tan XiaoBin, Wu Cong, Mao DeWen. Mechanism of action of intestinal flora in hepatic encephalopathy and related treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(10): 2375-2379. doi: 10.3969/j.issn.1001-5256.2020.10.047
[11]	Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
[12]	Li Qiang, Zhu QingLiang, Zhang HaiLong, Deng MingMing, Hu Qing, Wang ZiJie. Characteristics of intestinal flora before and after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(2): 333-337. doi: 10.3969/j.issn.1001-5256.2020.02.020
[13]	Guo XiaoXia, Hu Na, Lian XiaoXiao, Sun YuanPei, Li YuZhen, Lu: Lei, Ye YongAn, Li XiaoKe. Features of intestinal flora imbalance in patients with liver cirrhosis and related driving factors[J]. Journal of Clinical Hepatology, 2020, 36(7): 1527-1533. doi: 10.3969/j.issn.1001-5256.2020.07.016
[14]	Huang YunYi, Liu Yao, Zhang Qun, Shi Ke, Wang XianBo. Association of intestinal microecology with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2020, 36(4): 912-914. doi: 10.3969/j.issn.1001-5256.2020.04.045
[15]	Luan YuTing, Cai WenJun, Jiang ShiLi, Zhao ZhangQing, Gu HongTu, Yuan JiLi, Xing Feng, Lu: Jing, Liu ChengHai, Liu Ping, Mu YongPing. A comparative study of intestinal flora between hepatitis B cirrhosis patients with or without ascites[J]. Journal of Clinical Hepatology, 2020, 36(7): 1520-1526. doi: 10.3969/j.issn.1001-5256.2020.07.015
[16]	Wang DanDan, Song Jia, Zhang XiaoLan. Research advances in the role of gut microbiota in liver diseases[J]. Journal of Clinical Hepatology, 2019, 35(9): 2120-2123. doi: 10.3969/j.issn.1001-5256.2019.09.053
[17]	Huang Qian, Zhang HaiBo, Li JingTao, Wei HaiLiang, Yan ShuGuang, Hui Yi, Chang ZhanJie. Research advances in the mechanism of action of intestinal microecology in intrahepatic cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2355-2359. doi: 10.3969/j.issn.1001-5256.2019.10.050
[18]	Li PeiBo, Qin FanBo, Gong JianPing. Association between intestinal barrier and bacterial translocation in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1854-1857. doi: 10.3969/j.issn.1001-5256.2019.08.046
[19]	Zheng Wei, Zhang YongHong, Zhao Yan. Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1613-1615. doi: 10.3969/j.issn.1001-5256.2019.07.041

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (55) PDF downloads(8)

Gut microbiota in hepatitis B cirrhosis

DOI: 10.12449/JCH250324

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Gut microbiota in hepatitis B cirrhosis

DOI: 10.12449/JCH250324

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content